Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 9


Nordihydroguaiaretic acid impairs prostate cancer cell migration and tumor metastasis by suppressing neuropilin 1.

Li X, Fan S, Pan X, Xiaokaiti Y, Duan J, Shi Y, Pan Y, Tie L, Wang X, Li Y, Li X.

Oncotarget. 2016 Dec 27;7(52):86225-86238. doi: 10.18632/oncotarget.13368.


Modulation of insulin-like growth factor-1 receptor and its signaling network for the treatment of cancer: current status and future perspectives.

Jin M, Buck E, Mulvihill MJ.

Oncol Rev. 2013 Apr 22;7(1):e3. doi: 10.4081/oncol.2013.e3. eCollection 2013 Apr 22. Review.


Discovery of novel non-ATP competitive FGFR1 inhibitors and evaluation of their anti-tumor activity in non-small cell lung cancer in vitro and in vivo.

Wu J, Ji J, Weng B, Qiu P, Kanchana K, Wei T, Wang Y, Cai Y, Li X, Liang G.

Oncotarget. 2014 Jun 30;5(12):4543-53.


Synthesis, radiolabeling and initial in vivo evaluation of [(11)C]KSM-01 for imaging PPAR-α receptors.

Solingapuram Sai KK, Kil KE, Tu Z, Chu W, Finck BN, Rothfuss JM, Shoghi KI, Welch MJ, Gropler RJ, Mach RH.

Bioorg Med Chem Lett. 2012 Oct 1;22(19):6233-6. doi: 10.1016/j.bmcl.2012.08.010. Epub 2012 Aug 9.


Establishment of platform for screening insulin-like growth factor-1 receptor inhibitors and evaluation of novel inhibitors.

Tong LJ, Xie H, Peng T, Liu XF, Xin XL, Huang X, Chen SM, Liu HY, Li HL, Geng MY, Yin M, Ding J.

Acta Pharmacol Sin. 2011 Jul;32(7):930-8. doi: 10.1038/aps.2011.23. Epub 2011 Jun 6.


Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update.

Lü JM, Nurko J, Weakley SM, Jiang J, Kougias P, Lin PH, Yao Q, Chen C.

Med Sci Monit. 2010 May;16(5):RA93-100. Review.


Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach.

Li R, Pourpak A, Morris SW.

J Med Chem. 2009 Aug 27;52(16):4981-5004. doi: 10.1021/jm9002395. Review. No abstract available.


Nordihydroguaiaretic acid inhibits transforming growth factor beta type 1 receptor activity and downstream signaling.

Li F, Pham JD, Anderson MO, Youngren JF.

Eur J Pharmacol. 2009 Aug 15;616(1-3):31-7. doi: 10.1016/j.ejphar.2009.06.012. Epub 2009 Jun 17.


Nordihydroguaiaretic acid inhibits an activated fibroblast growth factor receptor 3 mutant and blocks downstream signaling in multiple myeloma cells.

Meyer AN, McAndrew CW, Donoghue DJ.

Cancer Res. 2008 Sep 15;68(18):7362-70. doi: 10.1158/0008-5472.CAN-08-0575.

Supplemental Content

Support Center